Medical division star performer at Graseby:
This article was originally published in Clinica
UK instruments group Graseby reported a 22% increase in sales by the medical division in the first quarter of 1995, boosted by orders from the UK NHS. Order intake grew 20% in the period with the new 9000 series ambulatory infusion pumps accounting for the major proportion. Despite the strong performance of the medical division, Graseby's total first quarter sales were 8% down on last year and group profit was unchanged from the 1994 first quarter.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.